Researchers at Boston Children's Hospital have successfully reversed type 1 diabetes in a mouse model by infusing blood stem cells pre-treated to produce more of a protein called PD-L1, which is deficient in mice (and people) with type 1 diabetes. The cells curbed the autoimmune reaction in cells from both mice and humans and reversed hyperglycemia in diabetic mice.
Findings were published today in Science Translational Medicine. "There's really a reshaping of the immune system when you inject these cells," says Paolo Fiorina, MD, PhD, of Boston Children's, senior investigator on the study.
The study shows that the treated stem cells, given to mice, home to the pancreas where islet cells are made. Almost all the mice were cured of diabetes in the short term, and one third maintained normal blood sugar levels for the duration of their lives. The treatment was effective whether PD-L1 production was stimulated through gene therapy or pre-treatment with small molecules.
The powers of PD-L1
Previous studies have tried using immunotherapies for type 1 diabetes, aiming to curb the autoimmune attack on the body's islet cells. These attempts have failed, in part because the therapies have not targeted diabetes specifically. Autologous bone-marrow transplant -- infusing patients with their own blood stem cells to reboot their immune system -- has helped some patients, but not all.
"Blood stem cells have immune-regulatory abilities, but it appears that in mice and humans with diabetes, these abilities are impaired," says Fiorina, in Boston Children's Division of Nephrology. "We found that in diabetes, blood stem cells are defective, promoting inflammation and possibly leading to the onset of disease."
A team led by Fiorina and first author Moufida Ben Nasr, PhD, also of Boston Children's, began by profiling the transcriptome of blood stem cells to find out what proteins the cells are making.
Using a gene expression microarray, they found that the network of genetic regulatory factors (microRNAs) controlling production of PD-L1 is altered in blood stem cells from diabetic mice and humans. This prevents production of PD-L1, even early in the disease.
They further showed that PD-L1 has a potent anti-inflammatory effect in the context of type 1 diabetes.
PD-L1 is known as an immune "checkpoint" molecule. It binds to the PD-1 receptor (inhibitory programmed death 1) on the inflammatory T-cells that are activated to cause autoimmune reactions. This causes the T-cells to die or become anergic (or inactive).
When Fiorina, Ben Nasr and colleagues introduced a healthy gene for PD-L1 into the stem cells, using a harmless virus as the carrier, the treated cells reversed diabetes in the mice. Fiorina and colleagues also found they could achieve the same effect by treating the cells with a "cocktail" of three small molecules: interferon beta, interferon gamma and polyinosinic-polycytidylic acid.
"We think resolution of PD-L1 deficiency may provide a novel therapeutic tool for the disease," Ben Nasr says.
Further study will be needed to determine how long the effects of the cell therapy last and how often the treatment would need to be given. "The beauty of this approach is the virtual lack of any adverse effects, since it would use the patients' own cells," says Fiorina.
In collaboration with scientists from Fate Therapeutics (San Diego, Calif.), Fiorina and colleagues are working to optimize the small-molecule "cocktail" used to modulate the blood stem cells. The team has completed a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration to support the conduct of a clinical trial in type 1 diabetes.
The study was supported by EFSD/Sanofi European Research Programme, an American Heart Association (AHA) Grant-in-Aid and by Fate Therapeutics. Boston Children's Hospital and Fate Therapeutics have filed intellectual property covering pre-treatment of blood stem cells for immunoregulation.
Co-authors were Sara Tezza, Francesca D'Addio and Vera Usuelli of Boston Children's Hospital's Division of Nephrology; Chiara Mameli of Buzzi Children Hospital, Milan, Italy; Anna Maestroni of the International Center for T1D, Pediatric Clinical Research Center Fondazione Romeo ed Enrica Invernizzi, University of Milan; Domenico Corradi, Silvana Belletti and Gabriella Becchi of the University of Parma, Italy; Luca Albarello of Ospedale San Raffaele, Milan, Italy; Gian Paolo Fadini of the University of Padova, Italy; Christian Schuetz and James Markmann of Massachusetts General Hospital; Clive Wasserfall of the University of Florida, Gainesville; Leonard Zon of Boston Children's Stem Cell Research Program; and Gian Vincenzo Zuccotti of the International Center for T1D, University of Milan, and Buzzi Children Hospital, Milan.
Boston Children's Hospital, the primary pediatric teaching affiliate of Harvard Medical School, is home to the world's largest research enterprise based at a pediatric medical center. Its discoveries have benefited both children and adults since 1869. Today, more than 2,630 scientists, including nine members of the National Academy of Sciences, 14 members of the National Academy of Medicine and 11 Howard Hughes Medical Investigators comprise Boston Children's research community. Founded as a 20-bed hospital for children, Boston Children's is now a 415-bed comprehensive center for pediatric and adolescent health care. For more, visit our Vector and Thriving blogs and follow us on social media @BostonChildrens, @BCH_Innovation, Facebook and YouTube.